igf-2

Anti-IGF-2 Antibody (DX-2647) is a potent humanized monoclonal antibody targeting human insulin-like growth factor 2 (IGF-2), acting by disrupting its interaction with receptors such as IGF-1R and IR-A. The compound is an essential tool for investigating the role of the IGF axis in tumor proliferation and placental development, aiming to reverse abnormal tumor growth by inhibiting the IGF signaling axis.

Dalotuzumab (MK-0646) is a recombinant humanized IgG1 monoclonal antibody that specifically targets the insulin-like growth factor 1 receptor (IGF-1R). its mechanism of action involves the inhibition of IGF-mediated oncogenic signaling, which subsequently induces apoptosis and cell cycle arrest in tumor cells, and it has demonstrated enhanced antitumor efficacy when used in combination with other chemotherapeutic agents.

Istiratumab (M-6495), a bispecific monoclonal antibody, targets IGF-1R and ErbB3 receptors and facilitates their degradation via the proteasome pathway, offering potential for cancer research [1] [2] [3].

Anti-IGF1R/CD221 Antibody is a highly specific monoclonal antibody targeting the Type I Insulin-like Growth Factor Receptor (IGF-1R/CD221). By binding to the extracellular domain of IGF-1R, this antibody effectively blocks the interaction with its ligands IGF-1 and IGF-2, thereby inhibiting the activation of downstream PI3K/Akt and MAPK signaling pathways. It is a vital tool for researching tumor cell growth inhibition, apoptosis induction, and transmembrane signaling mechanisms.

BIIB022 is a human IgG4 monoclonal antibody (mAb) targeting IGF1R/CD221. It inhibits the phosphorylation of IGF-1 and IGF-2-induced IGF-1R and its downstream substrates. BIIB022 is applicable for research in lung cancer, pancreatic cancer, and colon cancer. The recommended isotype control is Human IgG4 kappa, Isotype Control.